Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT, 斯丹赛生物技术) is a biotechnology company focused on the development of cellular immunotherapies for the treatment of cancer. Its lead candidate is ICTCAR014, a CD19-targeting CAR-T cell therapy that expresses a dominant-negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells.